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Background: Many people with Parkinson disease do not have access to exercise programs that are specifically tailored to their
needs and capabilities. This mobile app allows people with Parkinson disease to access Parkinson disease–specific exercises that
are individually tailored using in-app demographic questions and performance tests which are fed into an algorithm which in turn
produces a video-guided exercise program.
Objective: To test the feasibility, safety, and signal of efficacy of a mobile app that facilitates exercise for people with Parkinson
disease.
Methods: A prospective, single-cohort design of people with Parkinson disease who had downloaded the 9zest app for exercise
was used for this 12-week pilot study. Participants, who were recruited online, were encouraged to exercise with the full automated
app for ≥150 minutes each week. The primary endpoints were feasibility (app usage and usability questions) and safety (adverse
events and falls). The primary endpoints for signal of efficacy were a comparison of the in-app baseline and 8-week outcomes
on the 30-second Sit-To-Stand (STS) test, Timed Up and Go (TUG) test, and the Parkinson’s Disease Questionnaire 8 (PDQ8).
Results: For feasibility, of the 28 participants that completed the study, 12 participants averaged >150 minutes of app usage
per week (3 averaged 120-150, 4 averaged 90-120, and 9 averaged less than 90 minutes). A majority of participants (>74%) felt
the exercise was of value (16/19; 9 nonrespondents), provided adequate instruction (14/19; 9 nonrespondents), and was appropriate
for level of function (16/19; 9 nonrespondents). For safety, there were no serious adverse events that occurred during the app-guided
exercise. There were 4 reports of strain/sprain injuries while using the app among 3 participants, none of which necessitated
medical attention. For signal of efficacy, there was improvement for each of the primary endpoints: STS (P=.01), TUG (P<.001),
and PDQ8 (P=.01).
Conclusions: Independent, video-guided exercise using a mobile app designed for exercise in Parkinson disease was safe and
feasible though there was variability in app usage. Despite this, the results provide evidence for a signal of efficacy as there were
improvements in 3 of the 3 outcomes.
Trial Registration: ClinicalTrials.gov NCT03459586; https://clinicaltrials.gov/ct2/show/NCT03459586
(JMIR Mhealth Uhealth 2020;8(10):e18985) doi: 10.2196/18985
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Exercise is an important therapy for people with Parkinson
disease. It has a positive effect on physical capacity and
physical/cognitive function, including improvements in gait,
mobility, posture, and balance [1]. In addition, several
meta-analyses and systematic reviews have concluded that
exercise and physical therapy improve many Parkinson
disease–specific motor and nonmotor symptoms [2-6].
Importantly, there are several lines of evidence, using rodent
Parkinson disease models and in humans with Parkinson disease,
that suggest a possible disease-modifying effect of exercise on
Parkinson disease [7-22].
Despite the evidence revealing the benefits of exercise in
Parkinson disease, many people with Parkinson disease do not
participate regularly in exercise and the reasons for this are
complex [23]. First, people with Parkinson disease have many
of the same type of inherent intrinsic and extrinsic barriers that
are present in healthy, older adults. These include a lack of
motivation, finances, knowledge, skill, accessibility to exercise
facilities, and transportation, among other things [24-26]. Many
of these issues are compounded in Parkinson disease because
of Parkinson disease–specific nonmotor symptoms, including
fatigue [27] and depression [28]. In addition, low outcome
expectation, lack of time, and fear of falling have been identified
as important perceived barriers to exercise in people with
Parkinson disease [29].
While exercise is not routinely recommended by neurologists
in the early course of Parkinson disease treatment [30],
neurologists are frequently the first to introduce the importance
of exercise to people with Parkinson disease. Typically, the
patient is referred to a physical therapist who will prescribe an
exercise program that is scaled to the person’s health and
functional status. Ideally, people with Parkinson disease will
continue to exercise independently or in a community program
after they have finished their therapy and then return to their
physical therapist every 6-12 months to recalibrate the exercise
program to meet the challenges of new and increasing
impairments brought on by disease progression. Unfortunately,
many have difficulty sustaining regular engagement in an
exercise program between physical therapy visits [24,31].
Therefore, a relatively large proportion fall back into previous
habits and discontinue their exercise after discharge from
supervised therapy. Subsequently, gained benefits are lost and
prospective benefits of continuing exercise therapy are
unrealized [32].
One solution that addresses many of the aforementioned barriers
to sustained exercise participation is a recently developed,
commercially available mobile app (9zest Parkinson’s Therapy
[33], a subsidiary of Moterum Technologies [34]), which was
developed by a software engineer with Parkinson disease. This
app uses self-report questions and app-guided performance tests
to assess status at baseline and progress the exercise program
over time. Using these self-report and performance metrics, the
app constructs a customized exercise program using a
proprietary algorithm. The app selects exercises from a library
of exercise videos specifically designed for people with
Parkinson disease and is calibrated to one’s current level of
function. The 9zest app also includes several behavior change
techniques, including prompts/cues, goal setting, graded tasks,
and performance feedback. Currently, there are a limited number
of apps reported in the literature that promote exercise or
physical activity for people with Parkinson disease [35,36].
The 9zest app specifically aims to mitigate many of the barriers
to exercise participation. First, the app can be used in the privacy
of one’s home. Because prominent barriers to participation
include lack of accessibility and limited time, this app allows
those with transportation problems or those in rural areas and
“medical/exercise deserts” to have access, at a convenient time,
to a semicustomized exercise program for people with Parkinson
disease. In addition, because it has periodic assessments, it helps
improve participant motivation through goal setting and
feedback [29]. Lastly, because the app is relatively low cost, it
is ideal for financially disadvantaged populations. While the
9zest app appears promising, it has not been evaluated
scientifically to determine its utility for people with Parkinson
disease. Therefore, Aim 1 was to test the feasibility (adherence
and user feedback) of using the app for independent exercise
over 12 weeks for people with Parkinson disease. Aim 2 was
to test the safety (adverse events and falls) and Aim 3 was to
detect a signal of efficacy for lower extremity strength,
functional gait, and quality of life in people with Parkinson
disease. Identifying signals of efficacy is important in early
studies, such as that described here, as they allow inference
about proof of concept and whether continued scientific
exploration using more rigorous clinical trials is warranted [37].
Methods
Study Design
A prospective, single-cohort design was implemented for this
pilot study wherein participants who had downloaded the
commercially available 9zest app were invited to participate in
this study via an in-app message. Based on responses to the
inclusion and exclusion criteria during in-app consenting,
qualified participants were invited to complete the in-app
baseline assessment (detailed later). These measures were used
by the app to construct an individualized 12-week exercise
program. All study-related tasks were conducted without direct
contact from a member of the research team. Participants were
instructed to be tested in the “on” Parkinson disease medication
state for testing and app-guided exercise. For Aim 1 (feasibility),
participation data (minutes of use) were recorded by the app
and analyzed over the 12-week intervention period. Additionally,
participants were asked questions about the usability of the app
at the conclusion of the 12-week study. For Aim 2 (safety),
adverse events data were tracked via an in-app question every
2 weeks of the 12-week study. Fall data were tracked via an
in-app question after every exercise session. Outcomes for Aim
3 (signal of efficacy) were assessed at baseline, 8 weeks, and
12 weeks. However, the primary endpoint for the signal of
efficacy was the 8-week measurement point as it was thought
that waning adherence or more drop outs would occur over time;
therefore, 8 weeks was chosen to optimize the ability to detect
a signal of efficacy. The 12-week measurement was secondary.
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People with Parkinson disease who had downloaded the
commercially available app were automatically invited to
participate in the study. Those meeting all inclusion criteria
(English speaking, between 40 and 75 years old, self-report
neurologist-diagnosed Parkinson disease, willingness to
participate in a 12-week study, able to stand unassisted for 10
minutes, and stable on Parkinson disease medications and deep
brain stimulation for 3 months prior to participation) and not
having any of the exclusion criteria (diagnosed with dementia;
comorbidities that would preclude exercise participation or
increase participant risk [eg, severe osteoarthritis/pain, stroke,
severe respiratory problems, traumatic brain injury,
neuromuscular disease, atrial fibrillation, poorly controlled
cardiovascular disease, limb amputation, osteoporosis]; vision
or hearing impairment that would interfere with app use; fall
that required physician evaluation [emergency visit, urgent care,
or hospitalization] within the past year; use of an assistive device
for walking; and currently exercising more than 60 minutes per
week on average) were invited to advance to consent using an
online form. This study was approved by the University of
Nevada, Las Vegas Institutional Review Board. Participants
were recruited online from a sample of convenience from July
2018 to May 2019, clinical trial registry (clinicaltrials.gov
[NCT03459586]) using social media advertisements, health
care provider referrals, and snowball recruitment strategies
wherein participants were encouraged to recruit other
participants among their acquaintances.
Sample Size Calculation
The sample size was estimated using Aim 3 and was calculated
with the “paired t tests using effect size module” in PASS 19.0
[38] (NCSS, LLC). The sample size estimation was based on
an effect size between 0.39 and 0.52 for the 30-second
Sit-To-Stand (STS) test from another exercise study for people
with Parkinson disease [39]. The analysis was based on a
one-sided test at 80% power with the significance level at .05
and a 15% dropout rate; this estimation was conservatively
based on the same exercise study for people with Parkinson
disease that had an 11.1% dropout rate [39]. With dropouts, a
sample size range between 30 (effect size=0.52) and 53
participants (effect size=0.39) was estimated.
Outcomes
Primary and secondary endpoints were all assessed via the app.
Principal analyses took place at the 8-week point and exploratory
analyses took place at the 12-week point. The primary endpoint
of feasibility (Aim 1) was assessed by in-app tracking of app
exercise in minutes. Usability was assessed using the following
statements at the conclusion of the 12-week study with a 5-point
Likert scale (5=strongly agree, 4=agree, 3=neutral, 2=disagree,
and 1=strongly disagree): (1) I believe this activity could be of
some value to me; (2) I thought the app provided adequate
instruction on the exercises; (3) I enjoyed using the app to help
me exercise; (4) I would recommend this app to others with
Parkinson disease; and (5) The exercises were appropriate for
my level of functioning.
The primary endpoint of safety (Aim 2) was assessed by tracking
adverse events (assessed every 2 weeks over 12 weeks with a
short in-app question asking if they have experienced any app
exercise–related adverse events). Participants were asked
questions about the occurrence of the following while doing
the app-guided exercises: strains/sprains, chest pain, shortness
of breath, and dizziness. If an event was reported, participants
were asked follow-up questions to record the details (ie, pain
rating, if it required medical attention, outcome). Safety was
also measured by asking about the occurrence of a fall/s and
other medical issues/events that occurred during the exercise
(assessed after every app exercise session using an in-app
question). In addition, at the conclusion of the 12-week study
participants were asked the following statement with a 5-point
Likert scale (strongly agree, agree, neutral, disagree, and
strongly disagree): I felt safe doing the exercises using the app.
The following endpoints for Aim 3 (signal of efficacy) were
assessed at baseline, and at the 8-week (primary) and 12-week
(secondary) measurement points as part of the in-app
assessment:
• 30-second STS, which is a measure of functional lower
extremity strength with good reliability in people with
Parkinson disease [40,41] and a minimal detectable change
(MDC) of 3 [40];
• Timed Up and Go (TUG), which is a test of mobility and
dynamic balance with evidence for good reliability in people
with Parkinson disease [42-44] and an MDC of 4.85 [45];
and
• Parkinson’s Disease Questionnaire 8 (PDQ8), which is a
shortened version of the PDQ39, a Parkinson
disease–specific quality of life measure, which has good
reliability in people with Parkinson disease [46-49] and an
MDC of 5.43 [45].
The STS and TUG tests were preceded by a demonstration video
and an explanation of the test prior to the assessment using a
built-in timer (Figure 1). In addition to the STS, TUG, and
PDQ8, the Global Rating of Change score was asked at the
conclusion of the 12-week study.
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Figure 1. An example (30-second Sit-To-Stand test) of the in-app performance-based assessment used as a primary endpoint for the study and also
used by the 9zest Smart to construct the exercise routine.
Exercise Intervention
Participants were encouraged to use the app on their phone or
tablet for at least 150 minutes per week (eg, 3-5 days per week
at 30-60 minutes each session) for 12 weeks. After registering
on the app and completing several self-report Likert scale
questions (ie, standing posture, tremors, balance, fall history,
turning in bed, body movements with activities of daily living;
Figure 2) and performance-based assessments (ie, STS, timed
360 degree turn, TUG, timed shirt removal), the 9zest app, using
a proprietary algorithm (9zest Smart), constructed an exercise
regimen for the participant’s level of function. The customized
exercise regimen was constructed from a library of over 1000
original exercise videos, developed by physical therapists. The
library consisted of exercise in the following categories: aerobic,
strengthening, balance, yoga based, range of motion/stretching,
meditation based, and speech therapy exercises. However,
because mobility was assigned as the in-app goal for each
participant, the 9zest Smart algorithm drew exercises from the
strengthening, balance, and stretching categories. The 9zest
Smart, the app’s intelligent engine, determined the regimen and
levels of exercises for a user based on the most recent
assessment (Figures 3 and 4). Thus, the app chooses the exercise
program based on the primary goal (ie, mobility) and then uses
the responses from self-report questions and the data from
performance-based tests to determine the severity of the
Parkinson disease. From this information, the app selects
exercises that are consistent with the primary goal and at the
appropriate level of function based on one’s severity of
Parkinson disease. At preset intervals (generally after 2 weeks),
the app reassessed functional capacity using the same self-report
questions and performance-based measures. The 9zest Smart
algorithm adjusted the type, duration, and intensity of each
exercise in the constructed exercise regimen. All of the exercises
and dosing features are consistent with contemporary,
clinical-based physical therapy practice as determined by the
physical therapy development team who helped build the
exercise library.
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 10 | e18985 | p. 4https://mhealth.jmir.org/2020/10/e18985
(page number not for citation purposes)
Landers & EllisJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Figure 2. An example of an in-app self-report question that is used in the algorithm to construct the exercise program.
Because app-guided exercises are typically performed
independently, safety was a primary concern in the development.
All exercises in the library were deemed safe for people with
Parkinson disease by the physical therapy development team
for level of impairment and function. However, because this
had not been scientifically vetted, it became a primary aim of
this study. An additional safety feature was an audiovisual
demonstration of each exercise to ensure that the exercise was
performed with the proper technique. After the demonstration,
the participant would then follow along with the audiovisual of
the exercise in real time (Figures 3 and 4). If participants were
deemed a fall risk by the in-app assessment, then all balance
exercises would be scaled to level of function. For example, the
balance exercise may be performed in sitting or at a
counter/chair with hand contact (Figure 5). The exercise library
consists of many variations of the same exercise (eg, standing,
standing with support, sitting and lying down) and the decision
on which exercise is selected for the exercise regimen is
determined by the in-app assessment. Thus, the 9zest Smart
algorithm would select an appropriate exercise variation with
the intent of minimizing the risk for an injury or a fall.
Additionally, before the session started, a warning message was
displayed asking the participant to skip any exercises that might
cause any pain or imbalance. Lastly, the in-app instruction
reminded participants to work within their own limits to avoid
any injury or fall.
JMIR Mhealth Uhealth 2020 | vol. 8 | iss. 10 | e18985 | p. 5https://mhealth.jmir.org/2020/10/e18985
(page number not for citation purposes)
Landers & EllisJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Figure 3. An example of an exercise program.
Figure 4. An example of a specific app-guided exercise (b).
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Figure 5. An example of graded exercises based on level of function.
Data Analysis
Data were analyzed using SPSS version 24.0 (IBM SPSS
Statistics for Windows) and α=.05 (where α is a priori level of
significance). For Aim 1 (feasibility), basic descriptive statistics
were used for in-app tracked exercise minutes and participants’
responses to Likert scale questions. For Aim 2 (safety), basic
descriptive statistics were used for the number of adverse events,
falls, and a Likert-style question on whether the app was safe.
For Aim 3 (signal of efficacy), the primary endpoint of the pre
and 8-week outcome measures were analyzed using paired t
tests to determine if app-guided exercise improved outcomes
over the first 8 weeks of the study. In addition, the number of
participants who improved beyond the MDC was tabulated for
each of the primary endpoints. For the secondary endpoint of
the 12-week outcomes and to determine if improvement
continued after the 8-week measurement point, a one-way
repeated measures ANOVA was used to compare the pre,
8-week, and 12-week outcomes. Descriptive statistics were used
to report the results of the Global Rating of Change responses.
To determine if there was a dosing effect, those who used the
app as instructed (≥150 minutes per week) were compared with
those who did not using a 2 (≥150 minute average per week:
yes or no) × 2 (time: premeasurement, 8-week measurement)
mixed factorial ANOVA. To explore this further, Pearson
correlational coefficient analyses were performed to determine
if the minutes of app use was associated with overall
improvement (8-week measurement – premeasurement) for
each of the 3 primary endpoints (ie, STS, TUG, and PDQ8).
Results
Recruitment
A total of 28 participants (mean age in years 62.1 [SD 9.6],
mean years since diagnosis 3.3 [SD 2.5]; males=6; females=14,
and unknown=8) completed the 12 weeks of the study (Figure
6). There were no statistically significant differences between
the dropouts and participants that completed the trial for age,
sex, and years since diagnosis (Table 1).
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Figure 6. CONSORT flow diagram of study participants.
Table 1. Means, proportions, and statistical comparisons for participant demographics for those who completed the trial and dropouts.
P valueDropoutsParticipants who completed the trialDemographics
NAa1928N





.244.7 (4.4)3.3 (2.5)Years since diagnosis, mean (SD)
aNA: not applicable.
Aim 1 (Feasibility)
As much as 12 of the 28 participants averaged more than 150
minutes of app usage per week. The remaining 16 participants
averaged the following: 120-150 minutes (n=3), 90-120 (n=4),
and <90 minutes (n=9). Of the 19 respondents (9 did not
respond), a majority felt the app exercise was of value (47%
[9/19] strongly agreed, 37% [7/19] agreed, 5% [1/19] neutral,
11% [2/19] strongly disagreed), provided adequate instruction
(53% [10/19] strongly agreed, 21% [4/19] agreed, 11% [2/19]
neutral, 5% [1/19] disagreed, 11% [2/19] strongly disagreed),
was enjoyable (47% [9/19] strongly agreed, 26% [5/19] agreed,
16% [3/19] neutral, 11% [2/19] strongly disagreed), would
recommend to other people with Parkinson disease (53% [10/19]
strongly agreed, 26% [5/19] agreed, 5% [1/19] neutral, 16%
[3/19] strongly disagreed), and was appropriate for my level of
function (37% [7/19] strongly agreed, 47% [9/19] agreed, 5%
[1/19] disagreed, 11% [2/19] strongly disagreed).
Aim 2 (Safety)
There were no reported bouts of dizziness, falls, chest pain, or
other medical events/issues during the app-guided exercise but
there was 1 report of shortness of breath that resolved without
the need for medical attention. There were 4 reports of
strain/sprain injuries (3 participants: low back pain and 3
episodes of knee pain), none of which necessitated medical
attention. Of the 19 respondents (9 did not respond), a majority
felt the app exercise was safe (63% [12/19] strongly agree, 21%
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[4/19] agree, 5% [1/19] neutral, and 11% [2/19] strongly
disagree).
Aim 3 (Signal of Efficacy)
There was a statistically significant improvement for each of
the 3 primary endpoints. The STS improved from the
premeasurement, mean 11.6 (SD 4.0), to the 8-week
measurement, mean 14.3 (SD 4.7; P=.01; Hedges g=0.59; 95%
CI 0.16-1.04). At the 8-week point, 15/28 (54%) improved
beyond the MDC on the STS. The TUG improved from the
premeasurement, mean 11.2 (SD 3.9), to the 8-week
measurement, mean 8.5 (SD 2.6; P<.001; Hedges g=.80; 95%
CI 0.46-1.18). At the 8-week point, 8/28 (29%) improved
beyond the MDC on the TUG. Lastly, the PDQ8 improved from
the premeasurement, mean 6.8 (SD 5.0), to the 8-week
measurement, mean 4.1 (SD 5.0; P=.01; Hedges g=0.53; 95%
CI 0.14-0.94). At the 8-week point, 6/28 (21%) improved
beyond the MDC on the PDQ8.
At the conclusion of the 12-week study, 63% (12/19, 9
nonrespondents) felt their condition was better using the Global
Rating of Change score. The results of the ANOVAs
(premeasurement, 8-week, and 12-week measurements) suggest
that there were no additional improvements from the 8-week
to the 12-week measurement points for the STS (P>.99), TUG
(P>.99), and PDQ8 (P=.94). There were no statistically
significant interactions for the factorial ANOVAs to test dosing
effect: STS (P=.39), TUG (P=.41), and PDQ8 (P=.86).
Likewise, there were no statistically significant correlations for
the average time of app exercise usage and change scores on




The main purpose of this study was to test the feasibility, safety,
and signal of efficacy of the 9zest app for people with Parkinson
disease. Results of this study suggest that independent,
video-guided exercise using the 9zest mobile app, designed for
exercise for people with Parkinson disease, may be safe and
feasible with considerable variability in app usage. A majority
of participants felt the app-guided exercise was of value and
enjoyable, and would recommend it to other people with
Parkinson disease. A majority of participants (16/19, 84%) felt
the app-guided exercise was not only safe but also appropriate
for their current level of function. Despite the variability in app
usage, the results suggest a signal of efficacy as there were
statistically significant improvements on all 3 outcome
measurements (P=.01 for STS; P<.001 for TUG; and P=.01 for
PDQ8). Additionally, a majority of participants (12/19, 63%)
felt that their condition had improved over the 12 weeks of the
study. Based on these promising data, the 9zest app may be a
safe, feasible, and useful technology for people with Parkinson
disease as an adjuvant to a formalized physical therapy program
or for those who wish to exercise independently or who do not
have access to a physical therapist or Parkinson disease–specific
exercise instruction because they live in a rural or underserved
community. However, caution is warranted as larger,
well-controlled trials are needed to draw more definitive
conclusions. While the study was not designed to make cause
and effect inferences, the results suggest an association between
exercising via the app and improvement in lower extremity
strength (STS), dynamic balance and mobility (TUG), quality
of life (PDQ8), and overall improvement (Global Rating of
Change). These results are consistent with a beneficial effect
of independent exercise using other smartphone apps in other
clinical populations [50].
It is important to note that the design of this study was such that
participants did not have any contact with members of the
research team and all assessments and training were done with
in-app programming. This was certainly advantageous from a
research resource perspective and it does mimic real-world use
of this commercially available app; however, the lack of direct
researcher contact/interaction and the requests to carry out
assessments may have contributed to the poor on-boarding rate
(Figure 6). The major reason for the poor onboarding rate may
be that the request to provide demographic information and to
perform assessments may have deterred participation as 436
prospective participants expressed interest in participating in
the study but only 74 participants provided demographic data
and completed outcome measures. This may be due to
participant burden or concerns related to privacy (eg, not
wanting to share demographic information). Losing 27 after
completing assessments (ie, not starting the intervention) may
be due to lack of interest or lack of follow through. The lack of
interaction with a health care professional or coach may have
contributed to the poor on-boarding and retention/adherence
rates.
It is noteworthy that only 43% (12/28) of the participants
reached the target of at least 150 minutes of app-guided exercise
per week. There was considerable variability in usage of the
app for exercise. Because the app was used independently with
no supervision, it is possible that some participants may have
had the app on and running but were not actually performing
the exercise along with the video, thereby inflating participation
rates. However, due to the study design, there is no way of
knowing whether this occurred or not. Additionally, there is no
way of knowing if participants “dropped-in” to another exercise
program during the 12-week study. Regardless, 2 analyses
(mixed factorial ANOVAs and correlational analyses) were
conducted to determine if there was a dose effect of app usage
on the outcome measures. The results of these analyses did not
indicate that there was a dose effect and the very low
correlations support this notion despite the fact that other
exercise and smartphone app studies have linked exercise
exposure to efficacy [51]. Further investigation into the dosing
of the 9zest app-guided exercise using a more rigorously
controlled design is warranted.
Based on the results of Aim 3, it is clear that the associations
of improvement in the 3 main outcomes measures occurred
during the first 8 weeks of the study. There were no statistically
significant improvements from the 8-week measurement point
to the 12-week measurement point for any of the outcome
measures. This suggests that the improvement may have
plateaued by the 8-week measurement point. However, the
Global Rating of Change question, asked at the 12-week
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measurement point, indicates that a majority felt their condition
had improved over the duration of the study.
Behavior change elements integrated into the app may have
helped adherence to the app-guided exercise. For instance,
incorporating remote Parkinson disease–specific peer coaching
[52] or remote supervision by a physical therapist [53] to
promote app use may be a helpful way to encourage adherence
and promote accountability [52]. While the app currently has
several behavior change techniques, including prompts/cues,
goal setting, graded tasks, and outcome feedback, to promote
exercise that are consistent with other apps for exercise [54,55],
these may have been less personalized compared with
approaches implemented by someone trained to address behavior
change like a physical therapist. By contrast, it is possible that
the behavior change elements in the study were ineffective at
promoting adherence to the research study or the exercise
program. It is also plausible that the app was not engaging
enough or lacked the optimized motivational prompts to promote
adherence.
Limitations
The most prominent limitation of the study was the poor
onboarding rate entering the study. There was a poor yield from
those who were invited to participate (74/436, 16.9%) and a
high dropout rate once participants had completed the baseline
measurements and started the exercise (19/47, 40%). These
challenges are not unique to this study as other app-based studies
have also had similar struggles with recruitment/yield and
dropout [56]. As much as 7 of the 19 dropouts had problems
with the app or technology, which may be an inherent
app-related problem or simply a challenge for older adults using
unfamiliar technology. This suggests that some human
interaction (eg, a remote health care professional/coach) in
studies like this, especially in the early stages of research, may
be important design elements to promote better onboarding and
adherence. The poor yield and high dropout rate resulted in a
considerably smaller sample size than was estimated and was
also smaller than the a priori sample size estimate. The study
participants were also a sample of convenience which may have
resulted in a biased sample of those comfortable with the
technology and those who were already motivated to exercise.
While the sample size was sufficient for the primary endpoints
of the study, it was likely underpowered for the Aim 3 factorial
ANOVAs. It is also important to note that low levels of app use
do not necessarily equate to actual exercise levels as it is
possible that participants were exercising without the app.
Another limitation of the study was the remote testing of
performance-based measures such as the STS and TUG, which
have not been psychometrically vetted using a remote test. Two
participants strongly disagreed that the app was safe. In fact,
these same 2 participants strongly disagreed on every Likert
question despite both being regular users of the app and both
improving over the course of the study. There were no consistent
characteristics, patterns, or themes in these participants’ data.
It is possible that they may have misinterpreted the direction of
the scale. Lastly, adverse events were only asked every 2 weeks
and this length of time may have increased the chance for recall
bias (ie, under- or over-reporting because of poor memory).
Conclusion
For those participants who completed this study, independent,
video-guided exercise using the 9zest mobile exercise app for
people with Parkinson disease was safe and feasible and a
majority of participants felt the app-guided exercise was
enjoyable, provided adequate instruction, and would recommend
it to others. While this study was not designed to determine
cause and effect, the results provide evidence for a signal of
efficacy as there were improvements in lower extremity
functional strength, mobility and dynamic balance, and quality
of life after 8 weeks of participation which were sustained at
12 weeks. The poor onboarding and adherence may suggest a
limited generalizability only to those that are able to interact
successfully with the technology.
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